Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 201

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 201
---
 than prevailing market prices and/or the prices at which public investors purchased our securities in the open market, and therefore such Selling Securityholders may generate positive rates of return on their investment that would not be available to public shareholders that acquired their securities at higher prices. For example, based on the closing price of our Common Stock of $6.47 per share as of July 23, 2025, the shares purchased by the Sponsor would experience a potential profit of up to approximately $6.466 per share with respect to sales of the Common Stock received in consideration of the founder shares. The table below provides, as of the date of this prospectus, information regarding the beneficial ownership of our shares of Common Stock of each Selling Securityholder, the number of shares of Common Stock that may be sold by each Selling Securityholders under this prospectus and that each Selling Securityholders will beneficially own after this offering. We have based percentage ownership on 27,064,633 shares of Common Stock outstanding as of the date of this prospectus.

127

Because each Selling Securityholder may dispose of all, none or some portion of their securities, no estimate can be given as to the number of securities that will be beneficially owned by a Selling Securityholder upon termination of this offering. For purposes of the table below, however, we have assumed that after termination of this offering none of the securities covered by this prospectus will be beneficially owned by the Selling Securityholder and further assumed that the Selling Securityholder will not acquire beneficial ownership of any additional securities during the offering. In addition, the Selling Securityholder may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose of, at any time and from time to time, our securities in transactions exempt from the registration requirements of the Securities Act after the date on which the information in the table is presented. Unless otherwise indicated below, the address of each Selling Securityholder listed in the tables below is c/o Liminatus Pharma, Inc., 6 Centerpointe Drive #625, La Palma, California 90623.

| ​                                | ​ |            ​ | ​ |          ​ | ​ | ​            | ​ | ​        |
| ​                                | ​ |       Number |   |          ​ |   | Number       |   | ​        |
| ​                                | ​ | Beneficially | ​ |     Number | ​ | Beneficially | ​ | Percent  |
| ​                                | ​ |        Owned | ​ | Registered | ​ | Owned